04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
07:00 , Oct 3, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Ovarian cancer Neuronal precursor cell expressed developmentally downregulated 8 (NEDD8); cullin 4A (CUL4A) Cell culture and human tissue studies suggest inhibiting CUL4A could help treat...
07:00 , Apr 1, 2010 |  BC Innovations  |  Targets & Mechanisms

Unlocking thalidomide

Thalidomide has been used in humans since the 1950s, but the molecular mechanisms responsible for its known therapeutic and teratogenic effects are not well characterized. Researchers in Japan have now provided insight into the latter...
07:00 , Jun 11, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Skin cancer Cullin 4A (CUL4A) A study in mice and in cell culture suggests that inhibiting CUL4A, a ubiquitin ligase, could...